Cost-effectiveness analysis of aflibercept in combination with FOLFIRI in the treatment of patients with metastatic colorectal cancer [PDF]
Farmacia Hospitalaria, 2014 Objectives: To estimate the incremental cost per life-year gained (LYG) of aflibercept in combination with FOLFIRI as second-line treatment in metastatic colorectal cancer (mCRC) patients previously treated with oxaliplatin.
M.ª Echave +10 more
doaj +1 more source
Full thickness macular hole case after intravitreal aflibercept treatment [PDF]
, 2015 BACKGROUND: The pathogenesis of macular hole formation is widely accepted as a tractional force at the vitreo-retinal interface in fovea. We report a case of macular hole after intravitreous aflibercept injection for age-related macular degeneration (AMD)
Apte, Rajendra S +4 more
core +2 more sources
Efficacy and safety of aflibercept in in vitro and in vivo models of retinoblastoma
Journal of Experimental & Clinical Cancer Research, 2016 Background To evaluate the inhibitory effects of aflibercept on the growth and subretinal invasion of retinoblastoma. Methods Xenotransplantation and orthotopic mouse models were created by injecting Y-79 cells subcutaneously and intravitreally ...
Dong Yoon Kim +3 more
doaj +1 more source
Optical Coherence Tomographic Angiography Imaging in Age-Related Macular Degeneration. [PDF]
, 2017 Optical coherence tomographic angiography (OCTA) is emerging as a rapid, noninvasive imaging modality that can provide detailed structural and flow information on retinal and choroidal vasculature.
Desai, Ria +5 more
core +3 more sources
Vascular Response to Sildenafil Citrate in Aging and Age-Related Macular Degeneration. [PDF]
, 2019 Age-related macular degeneration (AMD) - the leading cause of vision loss in the elderly - share many risks factors as atherosclerosis, which exhibits loss of vascular compliance resulting from aging and oxidative stress.
Agrawal, Rupesh +8 more
core +2 more sources
Molecular Therapy: Methods & Clinical Development, 2020 Several standard-of-care therapies for the treatment of retinal disease, including aflibercept, inhibit vascular endothelial growth factor (VEGFA). The main shortcoming of these therapies is potential undertreatment due to a lack of compliance resulting ...
Szilárd Kiss +7 more
doaj +1 more source
The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: A review [PDF]
, 2017 The acute and chronic effects of repeated intravitreal antivascular endothelial growth factor (VEGF) injections on intraocular pressure have not been fully characterized, and the development of sustained ocular hypertension could adversely affect ...
Bracha, Peter +4 more
core +1 more source
Indian Journal of OphthalmologyPurpose: To investigate the 12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration (nAMD) in eyes previously treated with aflibercept.
Wajiha J Kheir +3 more
doaj +1 more source
Characteristics and racial variations of polypoidal choroidal vasculopathy in tertiary centers in the United States and United Kingdom [PDF]
, 2017 PURPOSE: To evaluate the characteristics and racial variations amongst patients with polypoidal choroidal vasculopathy (PCV) in the United States and the United Kingdom.
Adelman, RA +10 more
core +1 more source
Neoplasia: An International Journal for Oncology Research, 2016 BACKGROUND & AIM: Aflibercept known as ziv-aflibercept in the United States is a soluble decoy receptor of both vascular endothelial growth factor (VEGF) receptor-1 and -2 known to inhibit the binding of VEGF and placental growth factor (PlGF) to VEGF ...
Takuji Torimura +11 more
doaj +1 more source